Leucocyte labeling: Preliminary clinical evaluation of RP517, the 99mTc-Leukotriene B4 receptor antagonist for infection/inflammation
- 1. Centro de Medicina Nuclear. Htal.Clinicas, UBA-CNEA, Buenos Aires, (Argentina)
- 2. Centro de Medicina Nuclear, Htal de Clinicas, UBA, Buenos Aires (Argentina)
- 3. Laboratorio Bacon SAIC (United States)
- 4. Dupont, Pharma, Philadelphia (United States)
Description
99mTc- Leukotriene B4 (LTB4) is a receptor antagonist RP517 that labels predominantly neutrophils, in whole blood. This new radiopharmaceutical has been developed for imaging infection and inflammation. Aim: We conducted this clinical trial to obtain the best protocol imaging and the efficacy of this novel agent in the detection of suspected infected/inflamed patients. Materials and Methods: RP517 was labelled with 15-20 mCi (555-740 MBq) 99mTc for each patient, with a labeling efficiency of 86-95%. Nine patients studied (F 3, M 6) with ages 45-83, suspected of bone, joint and soft tissue infection (8) and one with fever of unknown origin (FUO). Laboratory, anatomical images and one other scintiscan (MDP, Gallium or 99mTc-ciprofloxacin) were used for evaluation. Acquisition protocol: flow, 30 min, 1, 2, 3, 4 - 24h planar or SPECT images if required. Results were compared to histology, cultures, the clinical derivation and follow up. Scans were classified as positive if abnormal uptake persisted through the 24h images or negative when absent pathological uptake or when positivity faded in later images. Results: No adverse reaction encountered. Image protocol modified to a flow, 30 min, 4 and 24h acquisitions. Early bladder excretion and intestinal activity requires previous cleansing enemas and food restrain. Late bone marrow activity is less visible than with in vitro leucocyte labeling. Coincident images were obtained in 3 True Positive, in 5 True Negative except in a hip prosthesis where Gallium and 99mTc-ciprofloxacin showed positivity and RP517 was False negative. Conclusions: A kit should be produced in order to make it available for Nuclear Medicine Departments. Known advantages of RP517 is the lack of in vitro cell labeling manipulation. We do not recommend investigation of FUO or abdominal pathologies. A larger series must be studied in order to be able to obtain statistics on joint bone and soft tissue infection/inflammation where this compound seems to be a valuable diagnostic tool
Additional details
Publishing Information
- Journal Title
- World Journal of Nuclear Medicine
- Journal Volume
- 1
- Journal Issue
- suppl.2
- Journal Page Range
- p. 61-62
- ISSN
- 1450-1147
Conference
- Title
- 8. Congress of the World Federation of Nuclear Medicine and Biology
- Dates
- 29 Sep - 2 Oct 2002
- Place
- Santiago (Chile)
INIS
- Country of Publication
- International Atomic Energy Agency (IAEA)
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 34023793
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Resource subtype / Literary indicator
- Conference
- Descriptors DEI
- ABDOMEN; BONE TISSUES; DIAGNOSIS; GASTROINTESTINAL TRACT; INFLAMMATION; LABELLED COMPOUNDS; LABELLING; NEUTROPHILS; RADIOPHARMACEUTICALS; RECEPTORS; TECHNETIUM 99
- Descriptors DEC
- ANIMAL TISSUES; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY; BODY FLUIDS; CONNECTIVE TISSUE; DIGESTIVE SYSTEM; DRUGS; HOURS LIVING RADIOISOTOPES; INTERMEDIATE MASS NUCLEI; INTERNAL CONVERSION RADIOISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; LEUKOCYTES; MATERIALS; MEMBRANE PROTEINS; NUCLEI; ODD-EVEN NUCLEI; ORGANIC COMPOUNDS; PATHOLOGICAL CHANGES; PROTEINS; RADIOACTIVE MATERIALS; RADIOISOTOPES; SYMPTOMS; TECHNETIUM ISOTOPES; YEARS LIVING RADIOISOTOPES